DexCom (NASDAQ:DXCM) Stock Gets Price Target Boost from Canaccord Genuity Group

Posted by George Bondi on Nov 2nd, 2026

DexCom (NASDAQ:DXCM – Get Free Report) had its price target lifted by stock analysts at Canaccord Genuity Group from $90.00 to $97.00 in a research report issued on Friday, Benzinga reports. The brokerage currently has a “buy” rating on the medical device company’s stock. Canaccord Genuity Group‘s price objective would indicate a potential upside of 17.88% from the stock’s current price.

A number of other brokerages have also recently issued reports on DXCM. Barclays lifted their price objective on shares of DexCom from $115.00 to $120.00 and gave the company an “overweight” rating in a report on Friday. Benchmark raised their price objective on DexCom from $77.00 to $82.00 and gave the company a “buy” rating in a research note on Friday, July 31st. Weiss Ratings raised shares of DexCom from a “hold (c)” rating to a “hold (c+)” rating in a report on Tuesday, October 6th. Robert W. Baird set a $105.00 target price on shares of DexCom in a research note on Friday, July 31st. Finally, Truist Financial set a $102.00 target price on shares of DexCom and gave the company a “buy” rating in a report on Friday, September 18th. Two research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, DexCom has a consensus rating of “Buy” and a consensus price target of $93.70.

Read Our Latest Report on DXCM

DexCom Stock Performance

Shares of NASDAQ DXCM opened at $82.29 on Friday. The company has a current ratio of 1.74, a quick ratio of 1.40 and a debt-to-equity ratio of 0.49. The company has a market capitalization of $30.69 billion, a P/E ratio of 32.27, a P/E/G ratio of 1.37 and a beta of 1.45. DexCom has a 12 month low of $54.11 and a 12 month high of $92.59. The stock has a 50 day moving average of $85.82 and a 200-day moving average of $74.65.

DexCom (NASDAQ:DXCM – Get Free Report) last issued its earnings results on Thursday, October 29th. The medical device company reported $0.73 earnings per share for the quarter, topping analysts’ consensus estimates of $0.68 by $0.05. The company had revenue of $1.34 billion for the quarter, compared to analyst estimates of $1.33 billion. DexCom had a return on equity of 37.77% and a net margin of 19.42%. DexCom’s revenue for the quarter was up 11.1% on a year-over-year basis. During the same period in the prior year, the firm earned $0.61 earnings per share. As a group, equities research analysts predict that DexCom will post 2.67 EPS for the current year.

Insiders Place Their Bets

In other DexCom news, EVP Michael Brown sold 1,700 shares of the company’s stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $85.48, for a total value of $145,316.00. Following the completion of the transaction, the executive vice president owned 98,185 shares in the company, valued at $8,392,853.80. This represents a 1.70% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Sadie Stern sold 2,565 shares of the firm’s stock in a transaction on Thursday, August 27th. The shares were sold at an average price of $88.37, for a total value of $226,669.05. Following the sale, the executive vice president directly owned 126,043 shares of the company’s stock, valued at approximately $11,138,419.91. This represents a 1.99% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 22,822 shares of company stock worth $1,920,193 in the last ninety days. Company insiders own 0.28% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Mather Group LLC. grew its position in shares of DexCom by 27.7% during the 3rd quarter. Mather Group LLC. now owns 563 shares of the medical device company’s stock valued at $49,000 after acquiring an additional 122 shares during the period. Fifth Third Wealth Advisors LLC increased its stake in shares of DexCom by 2.8% during the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 5,510 shares of the medical device company’s stock worth $475,000 after purchasing an additional 150 shares during the last quarter. Elevation Wealth Partners LLC raised its holdings in shares of DexCom by 61.0% in the 3rd quarter. Elevation Wealth Partners LLC now owns 401 shares of the medical device company’s stock worth $35,000 after purchasing an additional 152 shares during the period. MassMutual Private Wealth & Trust FSB raised its holdings in shares of DexCom by 15.4% in the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 1,147 shares of the medical device company’s stock worth $77,000 after purchasing an additional 153 shares during the period. Finally, Simplicity Wealth LLC raised its holdings in shares of DexCom by 5.4% in the 3rd quarter. Simplicity Wealth LLC now owns 3,169 shares of the medical device company’s stock worth $273,000 after purchasing an additional 162 shares during the period. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

DexCom Company Profile

(Get Free Report)

DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes. Its devices use a small wearable sensor to measure glucose levels in real time and transmit readings to compatible smartphones, receivers, smartwatches, and other connected devices, helping users monitor glucose trends and make informed decisions about their health.

The company’s product portfolio includes the Dexcom G7 and Dexcom G6 CGM systems, as well as Dexcom ONE and Dexcom ONE+ products offered in select markets.